Expression and prognostic relevance of annexin A3 in prostate cancer.

OBJECTIVES By differential quantitative protein expression, it has previously been shown that annexin A3 (ANXA3) expression is associated with prostate cancer. However little is known about the role and biology of ANXA3 in the human prostate. The aim of this study was to thoroughly analyze ANXA3 expression patterns and its potential as a prognostic marker in a large set of benign, preneoplastic, and neoplastic prostate tissue samples. METHODS Immunohistochemistry-based ANXA3 protein expression was analyzed for 1589 prostate cancers as well as smaller subsets of benign epithelium and high-grade prostatic intraepithelial neoplasia (PIN) in a tissue microarray format. RESULTS All samples of benign prostatic epithelium and PIN showed ANXA3 protein expression, with PIN lesions showing a decreased staining intensity compared with benign epithelium (p<0.0001). In cancer, ANXA3 protein expression was essentially reduced, resulting in a negative staining rate of 27.2%, which correlated with increasing pT stage and Gleason score (p<0.0001). ANXA3 status in cancer was shown to be an independent adverse prognostic factor and enabled substratification of the large group of intermediate-risk patients (n=969) into high- and low-risk subgroups. CONCLUSIONS ANXA3 represents a promising candidate tissue marker, and when combined with the standard prognostic parameters, is suggested to provide a more precise prediction of prognosis in the individual patient, therefore harboring the potential to contribute to future patient management.

[1]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[2]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[3]  M. Graefen,et al.  Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. , 2002, European urology.

[4]  Rong-Fong Shen,et al.  Identification and proteomic profiling of exosomes in human urine. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  F. Waldman,et al.  Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. , 1995, Human pathology.

[6]  S. Nilsson,et al.  Prostasome‐derived proteins capable of eliciting an immune response in prostate cancer patients , 2006, International journal of cancer.

[7]  S. Pentyala,et al.  Prostasomes: Current concepts , 2000, The Prostate.

[8]  S. Moss,et al.  Annexins: linking Ca2+ signalling to membrane dynamics , 2005, Nature Reviews Molecular Cell Biology.

[9]  T C Gasser,et al.  Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.

[10]  K. Pienta,et al.  Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis , 2002, The American journal of surgical pathology.

[11]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.

[12]  P. Härkönen.  Editorial comment on: expression and prognostic relevance of annexin A3 in prostate cancer. , 2008, European Urology.

[13]  Qingqing Wang,et al.  Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells , 2007, Journal of Cancer Research and Clinical Oncology.

[14]  G. Ronquist,et al.  Antiprostasome antibody titres in benign and malignant prostate disease. , 2005, Anticancer research.

[15]  Sung Goo Park,et al.  Annexin A3 is a potential angiogenic mediator. , 2005, Biochemical and biophysical research communications.

[16]  C. Roehrborn,et al.  Gleason Scores from Prostate Biopsies Obtained with 18-Gauge Biopsy Needles Poorly Predict Gleason Scores of Radical Prostatectomy Specimens , 1998, European Urology.

[17]  D. Bostwick,et al.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. , 2001, Human pathology.

[18]  D. Gleason.  Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions. , 1996, Urology.

[19]  Sascha Keller,et al.  Exosomes: from biogenesis and secretion to biological function. , 2006, Immunology letters.

[20]  M. Kattan,et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.

[21]  A. Lu,et al.  Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. , 2002, The Journal of urology.

[22]  H. Klocker,et al.  Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: Cancer association of annexin A3 , 2007, Proteomics.

[23]  Holger Moch,et al.  Tissue Microarrays: What Will They Bring to Molecular and Anatomic Pathology? , 2001, Advances in anatomic pathology.

[24]  A. Larsson,et al.  Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability. , 2006, Urologic oncology.

[25]  J. Blasko,et al.  Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. , 2001, Urology.

[26]  M. Lykourinas,et al.  Gleason Scores from Prostate Biopsies Obtained with 18-Gauge Biopsy Needles Poorly Predict Gleason Scores of Radical Prostatectomy Specimens , 1999, European Urology.

[27]  G. Multhoff,et al.  Immunostimulatory functions of membrane-bound and exported heat shock protein 70. , 2005, Exercise immunology review.

[28]  Peter C Albertsen,et al.  Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdom. , 2002, Surgical oncology.

[29]  L. Zitvogel,et al.  From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes. , 2002, Current opinion in molecular therapeutics.

[30]  Pierre I Karakiewicz,et al.  Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. , 2003, European urology.

[31]  T. Stamey,et al.  The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA , 2004, BJU international.